JP2025511161A - Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ - Google Patents

Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ Download PDF

Info

Publication number
JP2025511161A
JP2025511161A JP2024557983A JP2024557983A JP2025511161A JP 2025511161 A JP2025511161 A JP 2025511161A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2024557983 A JP2024557983 A JP 2024557983A JP 2025511161 A JP2025511161 A JP 2025511161A
Authority
JP
Japan
Prior art keywords
group
groups
substituted
unsubstituted
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511161A5 (cg-RX-API-DMAC10.html
Inventor
ジョン－クリストフ・ル・バイユ
ユルゲン・モル
サルヴィナ・タムマッカロ
イリス・ヴァルティンゴジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2025511161A publication Critical patent/JP2025511161A/ja
Publication of JP2025511161A5 publication Critical patent/JP2025511161A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024557983A 2022-04-04 2023-04-03 Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ Pending JP2025511161A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305439 2022-04-04
EP22305439.6 2022-04-04
PCT/EP2023/058693 WO2023194310A1 (en) 2022-04-04 2023-04-03 Therapeutic combination of kras g12c inhibitor and tead inhibitor

Publications (2)

Publication Number Publication Date
JP2025511161A true JP2025511161A (ja) 2025-04-15
JP2025511161A5 JP2025511161A5 (cg-RX-API-DMAC10.html) 2026-04-10

Family

ID=81326107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557983A Pending JP2025511161A (ja) 2022-04-04 2023-04-03 Ｋｒａｓ ｇ１２ｃ阻害剤及びｔｅａｄ阻害剤の治療的組合せ

Country Status (5)

Country Link
US (1) US20250295664A1 (cg-RX-API-DMAC10.html)
EP (1) EP4504203A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025511161A (cg-RX-API-DMAC10.html)
CN (1) CN118973584A (cg-RX-API-DMAC10.html)
WO (1) WO2023194310A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
US12662707B2 (en) 2024-01-24 2026-06-23 The Trustees Of Columbia University In The City Of New York MYC amplification drives resistance to pan-RAS inhibitors in pancreatic cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019338207B2 (en) * 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP4065230A1 (en) * 2019-11-27 2022-10-05 Genentech, Inc. Therapeutic compounds
WO2021204823A1 (en) 2020-04-07 2021-10-14 Sanofi (1 h-indol-5-yl)acrylamide derivatives as inhibitors of tead proteins and the hippo-yap1/taz signaling cascade for the treatment of cancer
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
CN116057042B (zh) 2020-07-30 2024-10-18 赛诺菲 丙烯酰胺取代的茚满化合物及其治疗用途

Also Published As

Publication number Publication date
US20250295664A1 (en) 2025-09-25
WO2023194310A1 (en) 2023-10-12
CN118973584A (zh) 2024-11-15
EP4504203A1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
JP5997763B2 (ja) タンパク質キナーゼ阻害剤としての大環状化合物
US9284298B2 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
US9598400B2 (en) Substituted quinoline compounds and methods of use
JP7193475B2 (ja) ジアリール大環状化合物を含む併用療法
CN117447479B (zh) 一种靶向肿瘤免疫激酶的吡咯并吡嗪衍生物、制备方法及其应用
US9333205B2 (en) Isoxazolo-quinazolines as modulators of protein kinase activity
EP4504203A1 (en) Therapeutic combination of kras g12c inhibitor and tead inhibitor
EP3233840A1 (en) Heterocyclic derivatives modulating activity of certain protein kinases
JP2023533464A (ja) がんを治療するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＫＲＡＳ阻害剤の組合せ
WO2012101032A1 (en) Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
CN103957709A (zh) Mek抑制剂与奥诺拉(aurora)a激酶选择性抑制剂的组合
WO2016115869A1 (zh) Flt3激酶的新型抑制剂及其用途
JP2019511554A (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
JP2023532675A (ja) ＥＧＦＲ突然変異ＮＳＣＬＣの治療に使用するための、ＣＢＰ／ｐ３００ブロモドメイン阻害剤およびＥＧＦＲ阻害剤の組合せ
TW202313050A (zh) 組合療法
WO2013177092A1 (en) Substituted alkynyl pyridine compounds and methods of use
JP2015510945A (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
CN114206869A (zh) Cxcr4抑制剂和其用途
US20250042918A1 (en) Compounds
HK40105285A (en) Application of compound in preparation of inhibitory drug targeting erbb2 mutant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260402